Shenzhen Kinwong Electronic Co.,Ltd. (China)

Shenzhen Kinwong Electronic Co., Ltd. is a company located in Shenzhen, China. The company was incorporated in 2001 and completed its shareholding reform in 2012. In July 2016, it successfully went public after passing the IPO review by the China Securities Regulatory Commission. Over the course of 30 years, Shenzhen Kinwong Electronic Co., Ltd. has developed a clear development strategy focused on major diseases and cultivating major varieties. The company's core products are patented traditional Chinese medicines, and it is committed to modernizing traditional Chinese medicine. It has played an important role in the field of cardiovascular and cerebrovascular diseases, which are considered major and chronic diseases. The company has established a three-dimensional product structure that focuses on the cardiovascular market, covers traditional advantages in traditional Chinese medicine, and cultivates major disease categories and major varieties. Based on the theory of treating the brain and heart together, Shenzhen Kinwong Electronic Co., Ltd. has developed and cultivated three exclusive patented products: Naoxintong Capsules, Wenxin Granules, and Danhong Injection. These products are used to treat common cardiovascular and cerebrovascular diseases such as stroke, arrhythmia, insufficient blood supply, and ischemic infarction. As a leading company in patented traditional Chinese medicine prescriptions, the company also has strong competitiveness in the field of gynecology, diabetes, and oncology. Its gynecological medicine, Honghe Fuyejie Solution, is a national third-class new traditional Chinese medicine and an exclusive product of the company. The company also covers products in pediatrics, anti-tumor, urology and digestive system, bone and joint, and respiratory system, including best-selling products such as Prostatitis Capsules, Ganshuang, Koulu Oral Liquid, and Xiasangju Granules. The company is capable of producing various dosage forms, including capsules, granules, and injections. In September 2018, Shenzhen Kinwong Electronic Co., Ltd. officially announced its transformation from a marketing-driven company to a product-driven and technology-driven company. It aims to transform from traditional Chinese medicine to the entire industry, including biopharmaceuticals, chemical drugs, medical devices, and internet medicine. The company also plans to transition from localization to globalization, steadily implementing its biopharmaceutical strategic plan. In the future, Shenzhen Kinwong Electronic Co., Ltd. will expand into the health industry, actively exploring biopharmaceuticals, internet medicine (mobile medicine, wearable medicine, e-commerce, etc.), health products, medical devices, and hospitals, with patented traditional Chinese medicine as its foundation. With China's strength and rise, the company will further deepen its global layout and strive to become a company with a market value of billions through product acquisitions and corporate mergers. The growth of Shenzhen Kinwong Electronic Co., Ltd. is attributed to China's market economy reform and healthcare system reform, as well as the favorable investment environment in the country. The company's vision is "Strong in China, Stepping into the World," and it will continue to contribute to regional economic development and the development of the pharmaceutical and medical industry, while also rewarding investors and society with excellent performance.